There seems to be some debate over whether there would be an advantage to making a big announcement at a conference like BioAmerica in Boston coming up, or simply putting out a PR.....some seem to think one is as good as the other.  Personally I disagree, but it depends on what they're announcing.

If they were to announce that they were being bought out by, say....Pfizer, that Pfizer was going to be acquiring Resverlogix for say 2.5 billion CDN, then I don't think it would matter whether it was a simple PR or an announcement at a big conference. Assuming a buyout price of 2.5 billion CDN and say 150 million shares fully diluted, RVX would simply jump to somewhere in and around $16.66 per share and trade in a very tight range until the deal was finalized and then it would cease to trade....

If, on the other hand, a deal was something other than a buyout....be it a CVR, or another licensing agreement, or an equity stake by a BP player.....or whatever.  If it was some type of deal with the potential to excite investors, but a deal that would see RVX continue to trade into the foreseeable future, then I think an announcement at a big conference would definitely be preferable.  

I referenced Ziopharm in a previous message...how they paid MD Anderson $50 million for a partnership deal, and then added another $7.5 million (all in stock)...the deal was sweetened with the extra $7.5 million to get the it done in time so that they could announce it at a JP Morgan Healthcare conference event.  Why?  I think the wisdome of the strategy was borne out in the trading that ensued....

Did it work?  It did for Ziopharm....from less than $3 in Sept/Oct of 2014 to $5 just before announcing the deal, and then up to near $15.  

Could something similar happen to RVX?  I don't think its out of the realm of possibility....it would depend on the nature of any deal and the players involved imo.  But if its an exciting deal (but not a buyout), with a major Pharma company....then I can think of worse places to announce it than at an investor conference for Biotechs filled with VC types along with Mutual and Hedge Fund managers in attendance.